DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 95 filers reported holding DYNE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,184,253 | -21.2% | 2,364,314 | -1.0% | 0.00% | 0.0% |
| Q2 2023 | $26,873,337 | +61.2% | 2,388,741 | +65.1% | 0.00% | – |
| Q1 2023 | $16,666,641 | -12.6% | 1,446,757 | -12.0% | 0.00% | -100.0% |
| Q4 2022 | $19,058,713 | +12.1% | 1,644,410 | +22.9% | 0.00% | – |
| Q3 2022 | $16,997,000 | +87.3% | 1,338,365 | +1.3% | 0.00% | – |
| Q2 2022 | $9,077,000 | -32.4% | 1,321,225 | -5.2% | 0.00% | – |
| Q1 2022 | $13,437,000 | -18.8% | 1,393,941 | +0.1% | 0.00% | – |
| Q4 2021 | $16,558,000 | -21.2% | 1,392,722 | +7.7% | 0.00% | -100.0% |
| Q3 2021 | $21,003,000 | -17.8% | 1,293,342 | +6.5% | 0.00% | 0.0% |
| Q2 2021 | $25,561,000 | +88.3% | 1,214,883 | +39.0% | 0.00% | – |
| Q1 2021 | $13,573,000 | -6.4% | 873,973 | +26.6% | 0.00% | – |
| Q4 2020 | $14,502,000 | +1497.1% | 690,582 | +1434.6% | 0.00% | – |
| Q3 2020 | $908,000 | – | 45,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |